Introduction: The use of ketamine as a recreational drug is on the increase among young adults attending clubs and parties. Recreational ketamine users have anecdotally reported increased lower urinary tract symptoms while using the substance. Methods: We describe the severe lower urinary tract symptoms experienced in 6 patients with chronic recreational ketamine use. We obtained a detailed history and physical examination along with further investigation to identify a relationship between recreational ketamine use and these symptoms. Results: The urine cultures were sterile in all cases. Intravenous urography was performed in 3 patients and demonstrated bilateral upper ureteric narrow, mild bilateral hydronephrosis and contracted bladder urodynamic studies showed detrusor instability with urinary leakage when the bladder was filled to a capacity of 30– 50 ml. Cystoscopy revealed a small capacity bladder with erythematous lesions throughout the bladder. Bladder biopsies were performed in 3 patients and showed up as chronic cystitis. Ketamine cessation along with intravesical sodium hyaluronate solution appeared to provide some symptomatic relief. Conclusion: Ketamine-associated urinary tract dysfunction appears to be a relatively new clinical phenomenon. The pathological mechanism of ketamine-associated urinary tract dysfunction is unknown and current management strategies are ketamine cessation along with intravesical sodium hyaluronate solution.

Keywords:
Adult, Bladder dysfunction, Urinary bladder, Urodynamic study, Voiding dysfunction, Ketamine, Bladder dysfunction
1.
Ivani G, Vercellino C, Tonetti F: Ketamine: A new look to an old drug. Min Anestesiol 2003;69:468–471.
2.
Dillon P, Copeland J, Jansen K: Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003;69:23–28.
3.
Koyama K: Effects of amygdaloid and olfactory tubercle stimulation on efferent activities of the vesical branch of the pelvic nerve and the urethral branch of the pudendal nerve in dogs. Urol Int 1991;47(suppl 1):23–30.
4.
Shahani R, Streutker C, Dickson B, Stewart RJ: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007;69:810–812.
5.
Oxley JD, Cottrell AM, Adams S, Gillatt D: Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 2009;55:705–708.
6.
Wood D, Cottrell A, Baker SC, Southgate J, Harris M, Fulford S, Woodhouse C, Gillatt D: Recreational ketamine: from pleasure to pain. BJU Int 2011;107:1881–1884.
7.
Middela S, Pearce I: Ketamine-induced vesicopathy: a literature review. Int J Clin Pract 2011;65:27–30.
8.
Picramenos D, Deliveliotis C, Alexopoulou K, Makrichoritis C, Kostakopoulos A, Dimopoulos C: Extracorporeal shock wave lithotripsy for renal stones in children. Urol Int 1996;56:86–89.
9.
Houwert RM, Roovers JP, Venema PL, Bruinse HW, Dijkgraaf MG, Vervest HA: When to perform urodynamics before mid-urethral sling surgery for female stress urinary incontinence? Int Urogynecol J Pelvic Floor Dysfunct 2011;21:303–309.
10.
Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY: Ketamine-associated bladder dysfunction. Int J Urol 2009;16:826–829.
11.
Chiew YW, Yang CS: Disabling frequent urination in a young adult. Ketamine-associated ulcerative cystitis. Kidney Int 2009;76:123–124.
12.
Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW: The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008;102:1616–1622.
13.
Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, Ma WK, Chui KL, Yiu MK, Chan YC, Tse ML, Lau FL: ‘Street ketamine’-associated bladder dysfunction: a report of ten cases. Hong Kong Med J 2007;13:311–313.
14.
Mason K, Cottrell AM, Corrigan AG, Gillatt DA, Mitchelmore AE: Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin Radiol 2011;65:795–800.
15.
Moore KA, Sklerov J, Levine B, Jacobs AJ: Urine concentrations of ketamine and norketamine following illegal consumption. J Anal Toxicol 2001;25:583–588.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.